The Ruella Lab at the University of Pennsylvania develops next-generation immunotherapies to treat lymphoid malignancies and autoimmune diseases. Our research bridges basic science, translational discovery, and clinical trials. By biobanking patient samples, we uncover mechanisms of resistance and toxicity—and use this knowledge to design smarter, more effective treatments. Our mission is simple: translate scientific discovery into real cures for patients.